UMass Memorial Introduces Minimally Invasive EUS-RFA Therapy to Extend Life of Pancreatic Cancer Patients
Pancreatic cancer remains one of the deadliest forms of cancer, with a five-year survival rate of just 13%. Most patients receive a diagnosis at an advanced stage, leaving limited treatment options and a challenging prognosis.
UMass Memorial Introduces Minimally Invasive EUS-RFA Therapy to Extend Life of Pancreatic Cancer Patients